Roche and Spanish firm Oryzon Genomics have teamed up to develop epigenetics-based medicines, in a deal that could see the Swiss big pharma pay out more than $500m in potential milestones.
Roche has bought the rights to Oryzon's class of lysine specific demethylase-1 (LSD1) inhibitors, of which the lead molecule ORY-1001 was granted orphan drug status in Europe in August last...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?